This summary explores how antimicrobial resistance (AMR) is framed within Health Technology Assessment (HTA) frameworks worldwide and Australia’s unique role in HTA reviews. It examines the pressing market failures hindering AMR investment and emphasises the pivotal economic role of vaccines in combatting AMR.
Key points from the Political Declaration on AMR, endorsed at the United Nations General Assembly (UNGA) in September 2024, are discussed, alongside country-specific initiatives designed at mitigating AMR, including Australia’s recent Health Technology Assessment (HTA) review.
This paper also spotlights Biointelect’s expertise in bringing innovative AMR solutions to the market and the impact of efforts such as the inaugural Australian Vaccine Value Chain Conference (AVVCC) on reshaping vaccine and antimicrobial development, valuation, and accessibility.
